Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 19 results.
User Information
Export Records
  1. 1.   Evaluation of Pharmacodynamic Responses to Cancer Therapeutic Agents Using DNA Damage Markers
  2. Wilsker,Deborah; Barrett, Allison M.; Dull,Angie; Lawrence,Scott; Hollingshead,Melinda; Chen, Alice; Kummar, Shivaani; Parchment,Ralph; Doroshow, James H.; Kinders,Robert
  3. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019, MAY 15; 25(10): 3084-3095.
  1. 2.   BRCA1 Haploinsufficiency Is Masked by RNF168-Mediated Chromatin Ubiquitylation
  2. Zong, Dali; Adam, Salome; Wang, Yifan; Sasanuma, Hiroyuki; Callen, Elsa; Murga, Matilde; Day, Amanda; Kruhlak, Michael J.; Wong, Nancy; Munro, Meagan; Chaudhuri, Arnab Ray; Karim,Baktiar; Xia, Bing; Takeda, Shunichi; Johnson, Neil; Durocher, Daniel; Nussenzweig, Andre
  3. Molecular cell. 2019, MAR 21; 73(6): 1267-+.
  1. 3.   LMTK3 confers chemo-resistance in breast cancer
  2. Stebbing, Justin; Shah, Kalpit; Lit, Lei Cheng; Gagliano, Teresa; Ditsiou, Angeliki; Wang, Tingting; Wendler, Franz; Simon, Thomas; Szabo, Krisztina Sara; O'Hanlon, Tim; Dean, Michael; Roslani, April Camilla; Cheah, Swee Hung; Lee, Soo-Chin; Giamas, Georgios
  3. ONCOGENE. 2018, JUN; 37(23): 3113-3130.
  1. 4.   Phosphorylated fraction of H2AX as a measurement for DNA damage in cancer cells and potential applications of a novel assay
  2. Ji, Jay; Zhang, Yiping; Redon, Christophe E.; Reinhold, William C.; Chen, Alice P.; Fogli, Laura K.; Holbeck, Susan L.; Parchment, Ralph; Hollingshead, Melinda; Tomaszewski, Joseph E.; Dudon, Quentin; Pommier, Yves; Doroshow, James H.; Bonner, William M.
  3. PLOS ONE. 2017, Feb 3; 12(2): e0171582.
  1. 5.   A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas
  2. Kummar, S.; Ji, J. P.; Morgan, R.; Lenz, H. J.; Puhalla, S. L.; Belani, C. P.; Gandara, D. R.; Allen, D.; Kiesel, B.; Beumer, J. H.; Newman, E. M.; Rubinstein, L.; Chen, A.; Zhang, Y. P.; Wang, L. H.; Kinders, R. J.; Parchment, R. E.; Tomaszewski, J. E.; Doroshow, J. H.
  3. Clinical Cancer Research. 2012, Mar; 18(6): 1726-1734.
  1. 6.   CHEK2 genomic and proteomic analyses reveal genetic inactivation or endogenous activation across the 60 cell lines of the US National Cancer Institute
  2. Zoppoli, G.; Solier, S.; Reinhold, W. C.; Liu, H.; Connelly, J. W.; Monks, A.; Shoemaker, R. H.; Abaan, O. D.; Davis, S. R.; Meltzer, P. S.; Doroshow, J. H.; Pommier, Y.
  3. Oncogene. 2012, Jan; 31(4): 403-418.
  1. 7.   Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas
  2. Kummar, S.; Chen, A.; Ji, J. P.; Zhang, Y. P.; Reid, J. M.; Ames, M.; Jia, L.; Weil, M.; Speranza, G.; Murgo, A. J.; Kinders, R.; Wang, L. H.; Parchment, R. E.; Carter, J.; Stotler, H.; Rubinstein, L.; Hollingshead, M.; Melillo, G.; Pommier, Y.; Bonner, W.; Tomaszewski, J. E.; Doroshow, J. H.
  3. Cancer Research. 2011, Sep; 71(17): 5626-5634.
  1. 8.   Radiosensitization of glioma cells by modulation of Met signalling with the hepatocyte growth factor neutralizing antibody, AMG102
  2. Buchanan, I. M.; Scott, T.; Tandle, A. T.; Burgan, W. E.; Burgess, T. L.; Tofilon, P. J.; Camphausen, K.
  3. Journal of Cellular and Molecular Medicine. 2011, Sep; 15(9): 1999-2006.
  1. 9.   Development of a Validated Immunofluorescence Assay for gamma H2AX as a Pharmacodynamic Marker of Topoisomerase I Inhibitor Activity
  2. Kinders, R. J.; Hollingshead, M.; Lawrence, S.; Ji, J. P.; Tabb, B.; Bonner, W. M.; Pommier, Y.; Rubinstein, L.; Evrard, Y. A.; Parchment, R. E.; Tomaszewski, J.; Doroshow, J. H.; Natl Canc Inst Phase 0 Clinical, T.
  3. Clinical Cancer Research. 2010, Nov; 16(22): 5447-5457.
  1. 10.   Tumors induce complex DNA damage in distant proliferative tissues in vivo
  2. Redon, C. E.; Dickey, J. S.; Nakamura, A. J.; Kareva, I. G.; Naf, D.; Nowsheen, S.; Kryston, T. B.; Bonner, W. M.; Georgakilas, A. G.; Sedelnikova, O. A.
  3. Proceedings of the National Academy of Sciences of the United States of America. 2010, Oct; 107(42): 17992-17997.
  1. 11.   CCAAT/enhancer binding protein delta (C/EBP delta, CEBPD)-mediated nuclear import of FANCD2 by IPO4 augments cellular response to DNA damage
  2. Wang, J.; Sarkar, T. R.; Zhou, M.; Sharan, S.; Ritt, D. A.; Veenstra, T. D.; Morrison, D. K.; Huang, A. M.; Sterneck, E.
  3. Proceedings of the National Academy of Sciences of the United States of America. 2010, Sep; 107(37): 16131-16136.
  1. 12.   Histone yH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers
  2. Redon, C. E.; Nakamura, A. J.; Zhang, Y. W.; Ji, J. P.; Bonner, W. M.; Kinders, R. J.; Parchment, R. E.; Doroshow, J. H.; Pommier, Y.
  3. Clinical Cancer Research. 2010, Sep; 16(18): 4532-4542.
  1. 13.   Proteomic Analysis of Nuclei Isolated from Cancer Cell Lines Treated with Indenoisoquinoline NSC 724998, a Novel Topoisomerase I Inhibitor
  2. Han, B. N.; Stockwin, L. H.; Hancock, C.; Yu, S. X.; Hollingshead, M. G.; Newton, D. L.
  3. Journal of Proteome Research. 2010, Aug 6; 9(8): 4016-4027.
  1. 14.   Monitoring Drug-Induced gamma H2AX as a Pharmacodynamic Biomarker in Individual Circulating Tumor Cells
  2. Wang, L. H.; Pfister, T. D.; Parchment, R. E.; Kummar, S.; Rubinstein, L.; Evrard, Y. A.; Gutierrez, M. E.; Murgo, A. J.; Tomaszewski, J. E.; Doroshow, J. H.; Kinders, R. J.
  3. Clinical Cancer Research. 2010, Feb; 16(3): 1073-1084.
  1. 15.   Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts
  2. Baschnagel, A.; Russo, A.; Burgan, W. E.; Carter, D.; Beam, K.; Palmieri, D.; Steeg, P. S.; Tofilon, P.; Camphausen, K.
  3. Molecular Cancer Therapeutics. 2009 8(6): 1589-1595.
  1. 16.   Postradiation sensitization of the histone deacetylase inhibitor valproic acid
  2. Chinnaiyan, P.; Cerna, D.; Burgan, W. E.; Beam, K.; Williams, E. S.; Camphausen, K.; Tofilon, P. J.
  3. Clinical Cancer Research. 2008 14(17): 5410-5415.
  1. 17.   In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide
  2. Kil, W. J.; Cerna, D.; Burgan, W. E.; Beam, K.; Carter, D.; Steeg, P. S.; Tofilon, P. J.; Camphausen, K.
  3. Clinical Cancer Research. 2008 14(3): 931-938.
  1. 18.   Inhibition of Hsp90 compromises the DNA damage response to radiation
  2. Dote, H.; Burgan, W. E.; Camphausen, K.; Tofilon, P. J.
  3. Cancer Research. 2006, Sep; 66(18): 9211-9220.
  1. 19.   Role of Nbs1 in the activation of the Atm kinase revealed in humanized mouse models
  2. Difilippantonio, S.; Celeste, A.; Fernandez-Capetillo, O.; Chen, H. T.; San Martin, B. R.; Van Laethem, F.; Yang, Y. P.; Petukhova, G. V.; Eckhaus, M.; Feigenbaum, L.; Manova, K.; Kruhlak, M.; Camerini-Otero, R. D.; Sharan, S.; Nussenzweig, M.; Nussenzweig, A.
  3. Nature Cell Biology. 2005, JUL; 7(7): 675-U56.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel